EUVIMEDEUVIMED entdecken
Crossref

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer

Shiyu Miao, Yinping Sun, Yanyi Qu, Luying Zhu, Zhiyuan Zhong, Fenghua Meng

Acta Biomaterialia · 2026-03 · 212 · 624-636

DOI: 10.1016/j.actbio.2025.12.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-03. Verfasst von Shiyu Miao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and …. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Proto-Oncogene Proteins p21(ras), Toll-Like Receptor 8, Lung Neoplasms. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS-mutant lung cancers pose significant clinical challenges. Despite promising advance in covalent KRAS G12C inhibitors, many patients with G12C mutation reveal limited responses, due to rapid emergence of resistance and heterogeneous nature of KRAS mutations. Here, we report a reduction-sensitive micellar system for the codelivery of a KRAS G12C inhibitor (adagrasib, KI) and a TLR7/8 agonist (R848, TA) (mKITA), aiming to synchronize direct oncogenic signaling blockade with potent immune modulation within tumor microenvironment (TME). In KRAS G12C-mutant lung cancer LLC cells, mKITA displayed enhanced autophagy and apoptosis, inducing marked immunogenic cell death at an optimal KI/TA molar ratio of 8/1. This in turn, stimulated dendritic cell (DC) maturation, proinflammatory cytokine secretion, and robust T cell activation-manifesting as a pronounced in situ vaccine effect. In an orthotopic LLC model, systemic administration of mKITA brought about significant survival benefits, and remodeled the suppressive TME by depleting immunosuppressive MDSCs, Tregs and M2M, and recruiting effector immune subsets (DCs, IFN-γ+CTLs, Th1). Notably, combination therapy with αPD-1 achieved 60% complete tumor eradication and long-term survival, accompanied by epitope spreading and humoral responses against both KRAS and WT1 antigens. These results suggest that mKITA is capable of enabling in situ vaccination and overcoming key barriers in KRAS-driven lung cancer. This strategy appears as a potential generalizable approach to orchestrate durable, multilayered antitumor immunity and address the clinical challenge of resistance and immunosuppression in KRAS-mutant lung cancers. STATEMENT OF SIGNIFICANCE: KRAS-mutant lung cancer represents a major clinical challenge due to its resistance to both targeted kinase inhibition and immunotherapy. Current strategies provide limited efficacy because of tumor heterogeneity, rapid adaptation, and the immunosuppressive TME. We develop a reduction-sensitive micellar nanoplatform (mKITA) that enables synchronized, spatiotemporally controlled co-delivery of a KRAS G12C inhibitor and a TLR7/8 agonist. mKITA induces autophagy- and apoptosis-associated ICD, and primes APCs to trigger robust in situ T cell activation. This strategy effectively remodels immunosuppressive TME by depleting MDSCs while recruiting CTLs and Th1 cells. In orthotopic lung cancer models, combining mKITA with αPD-1 achieves complete tumor regression and long-term survival in 60% of mice. This strategy offers a clinically translatable nanomedicine to overcome resistance in KRAS-driven lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7Proto-Oncogene Proteins p21(ras)Toll-Like Receptor 8Lung NeoplasmsImmunotherapyMicellesMutationAnimalsMiceCell Line, TumorHumansImidazolesTumor MicroenvironmentMice, Inbred C57BLDendritic CellsFemaleAutophagyMembrane Glycoproteins

Stichwörter der Autor:innen

Cancer immunotherapyImmune activationKRAS-mutant cancersMolecular targeted therapyNanomedicines

Substanzen

Toll-Like Receptor 7Proto-Oncogene Proteins p21(ras)Toll-Like Receptor 8MicellesImidazolesTlr7 protein, mouseresiquimodMembrane Glycoproteins

Autor:innen und Institutionen

  • Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China.
  • Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China; College of Pharm…
  • Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China. Electronic addre…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • National Key Research and Development Program of China Stem Cell and Translational Research

Zitieren

APA

Miao, S., Sun, Y., Qu, Y., Zhu, L., Zhong, Z., & Meng, F. (2026). Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer. Acta Biomaterialia, 212, 624-636. https://doi.org/10.1016/j.actbio.2025.12.045

Vancouver

Miao S, Sun Y, Qu Y, Zhu L, Zhong Z, Meng F. Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer. Acta Biomaterialia. 2026;212:624-636. doi:10.1016/j.actbio.2025.12.045

BibTeX
@article{Miao2026,
  author = {Miao, Shiyu and Sun, Yinping and Qu, Yanyi and Zhu, Luying and Zhong, Zhiyuan and Meng, Fenghua},
  title = {Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {212},
  pages = {624--636},
  doi = {10.1016/j.actbio.2025.12.045}
}
Kostenlos starten →